← All Market Monitors SANOR About SANOR

GLP-1 Market Monitor

GLP-1 medicines are reshaping diabetes and weight-loss care, driving a race for customers, capital and market share. The SANOR GLP-1 Market Monitor tracks the companies, deals and commercial developments shaping this market.

Updated 23 September 2026

Market Size

$79.0bn

Annual global market size · 2025

Market Growth

+9.2%

Forecast annual growth (CAGR) · 2025–2035

Ticker Activity

22

Last 12 months

Deal Activity

7

Last 12 months

Companies in the GLP-1 Market

Eli Lilly

Pharmaceutical manufacturer

Eli Lilly develops and manufactures medicines for diabetes, obesity, cancer and other diseases.

Market cap $1.1tn

Novo Nordisk

Other

Novo Nordisk develops and manufactures medicines for diabetes and obesity, including Ozempic and Wegovy (semaglutide).

Market cap $189.3bn

MannKind

Other

MannKind develops inhaled drug-delivery technology, including its Technosphere platform.

Revvity

Life sciences company

Revvity supplies tools and services for life sciences research and diagnostics.

Roche

Pharmaceutical manufacturer

Roche is a healthcare company headquartered in Basel, Switzerland, with businesses in pharmaceuticals and diagnostics.

Superluminal

Biotechnology company

Superluminal develops investigational medicines, including an obesity program targeting MC4R.

Hims & Hers

Other

Hims & Hers provides weight-management consultations, prescriptions and ongoing care through its telehealth platforms.

Market cap $6.8bn

Poolbeg Pharma

Other

Poolbeg Pharma develops investigational treatments and is funding an oral GLP-1 proof-of-concept trial alongside its POLB 001 TOPICAL trial.

Free Playbook

The Private Clinic Playbook

Grow revenue at each location and build a commercial model that can scale across a clinic group.

Sanor never sells your personal information. By providing this information you agree to Sanor’s Privacy Policy and Terms of Service.

Privacy Policy Terms of Service Disclaimer Sitemap

SANOR research follows the principles of ISO 20252:2019 and the ICC/ESOMAR International Code on Market, Opinion and Social Research and Data Analytics, and is conducted in line with our Independence Policy. Our published reports follow our Editorial Standards.

SANOR research is funded through advisory engagements and research licensing. We do not accept vendor sponsorship, paid placement, or advertising.

All publications are provided for general information only. They do not constitute medical, financial, or investment advice and do not account for the circumstances of any specific business or individual.

© 2026 SANOR Intelligence